Warshaw Burstein LLP | Warshaw Burstein Partners Martin Siegel and Brian Daughney Advise Houston-based Nexalin Technology on $9.6 Million IPO
This links to the home page
News & Publications

Warshaw Burstein Partners Martin Siegel and Brian Daughney Advise Houston-based Nexalin Technology on $9.6 Million IPO

Corporate partners Martin Siegel and Brian Daughney represented Nexalin Technology, Inc. as securities and general corporate counsel with respect to Nexilin’s initial public offering of 2,315,000 units which closed on September 20, 2022.

The IPO, underwritten on a firm commitment basis, raised new funds in the amount of $9.6 million for Nexalin, and its securities have been listed for trading on the Nasdaq Capital Markets tier of the Nasdaq Stock Market.

About Nexalin Technology, Inc.
Nexalin designs and develops innovative neurostimulation products to uniquely and effectively help combat the ongoing global mental health epidemic. All of Nexalin’s products are non-invasive and undetectable and, critically, can provide relief to those afflicted with mental health issues without adverse side effects. Nexalin previously developed an easy-to-administer medical device — referred to as Generation 1 or Gen-1 — that utilizes bioelectronic medical technology to treat anxiety and insomnia, without the need for drugs or psychotherapy. Nexalin has designed and developed new advanced waveform technology emitted at 15 milliamps through our existing medical device improved with a modern enclosure — referred to as Generation 2 or Gen-2 — which can penetrate deeper into the brain and the associated structures of mental illness, which Nexalin believes will generate enhanced patient response. The Gen-2 device was recently approved in China by the National Medical Products Administration (NMPA) for the treatment of insomnia and depression in China. In September 2018, Nexalin entered into a series of agreements with Wider Come Limited, a company formed under the laws of the People’s Republic of China (“Wider”), pursuant to which Nexalin and Wider have agreed to form a joint venture entity to be domiciled in Hong Kong to conduct a portion of our clinical research and implement a business distribution plan for our devices in China, Macau, Hong Kong, and Taiwan. Additional information about the Company is available at: https://nexalin.com/.

Read the Nexalin Technologies press release here (link).